We provide trade advice to complement the prevailing
expert consensus on Entera Bio. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Entera Bio income statement, its balance sheet, and the statement of cash flows. Potential Entera Bio investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Entera Bio investors may use each financial statement separately, they are all related. The changes in Entera Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Entera Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Entera Bio
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Entera Bio performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Entera Bio shares is the value that is considered the true value of the share. If
the intrinsic value of Entera is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Entera Bio. Please read more on our
fundamental analysis page.
How effective is Entera Bio in utilizing its assets?
Entera Bio reports assets on its Balance Sheet. It represents the amount of Entera resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Entera Bio aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect Entera volatility, please check the breakdown of all its
fundamentals.
Are Entera Bio Earnings Expected to grow?
The
future earnings power of Entera Bio involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Entera Bio factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Entera Bio
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Entera
expected earnings.
Entera Bio Gross Profit
Entera Bio Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Entera Bio previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Entera Bio Gross Profit growth over the last 10 years. Please check Entera Bio's
gross profit and other
fundamental indicators for more details.
Detailed Perspective On Entera Bio
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Entera Bio is not uncomon. Institutional investors typically avoid acquiring a high percentage of Entera Bio stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Entera is distributed among investors.
Ownership Allocation
Entera Bio retains a total of 21.06 Million outstanding shares. Entera Bio retains significant amount of outstanding shares owned by
insiders. An
insider is usually defined as a CEO, other corporate executive, director, or
institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently
losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
| Retail Investors48.43% | Insiders41.19% | Institutions10.38% |
| Retail Investors | 48.43 |
| Insiders | 41.19 |
| Institutions | 10.38 |
| 2010 | 2019 | 2020 | 2021 (projected) |
Revenues USD | 500 K | 236 K | 212.4 K | 266.74 K | Revenues | 500 K | 236 K | 212.4 K | 266.74 K |
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Entera Bio has an asset utilization ratio of 2.6 percent. This suggests that the company is making $0.026 for each dollar of assets. An increasing asset utilization means that Entera Bio is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets | 16.11 Million | 90.3 |
| Assets Non Current | 1.17 Million | 6.58 |
| Goodwill | 556,474 | 3.12 |
Are Entera Bio technical ratios showing a come-back?
Current semi deviation is at 3.82. Entera Bio is displaying above-average volatility over the selected time horizon. Investors should scrutinize Entera Bio independently to ensure intended market timing strategies are aligned with expectations about Entera Bio volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Entera Bio's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Entera Bio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Final Take On Entera Bio
While many of the other players within the biotechnology industry are still a little expensive, even after the recent corrections, Entera Bio may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor short any shares of Entera Bio at this time. The Entera Bio risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Entera Bio.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Entera Bio. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com